GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » 14-Day RSI

Cellectis (Cellectis) 14-Day RSI : 44.01 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-28), Cellectis's 14-Day RSI is 44.01.

The industry rank for Cellectis's 14-Day RSI or its related term are showing as below:

CLLS's 14-Day RSI is ranked better than
56.06% of 1575 companies
in the Biotechnology industry
Industry Median: 44.62 vs CLLS: 44.01

Competitive Comparison of Cellectis's 14-Day RSI

For the Biotechnology subindustry, Cellectis's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Cellectis's 14-Day RSI falls into.



Cellectis  (NAS:CLLS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis  (NAS:CLLS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Cellectis 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Cellectis's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Launch of Follow-On Offering

By Stock market mentor Stock market mentor 02-02-2023

Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

By Stock market mentor Stock market mentor 01-17-2023

Cellectis Announces Pricing of Follow-On Offering

By Stock market mentor Stock market mentor 02-03-2023